Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06926881 · ClinicalTrials.gov registry record · NA
OLE Therapy With BE Patients in Home Care Study
A NA study of Bronchiectasis and Pulmonary Exacerbation, sponsored by Delve Health.
- Recruiting
- Registry status
- NA
- Development phase
- 85
- Enrollment target
- 4
- Study locations
NCT06926881: Recruiting NA study of Bronchiectasis and Pulmonary Exacerbation, sponsored by Delve Health.
NCT06926881 is a NA study of Bronchiectasis and Pulmonary Exacerbation that is actively recruiting participants, run by Delve Health. The registered enrollment target is 85 participants, below the 381-participant average among 13 other Bronchiectasis trials with a reported enrollment target (78% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06926881, a NA study of Bronchiectasis and Pulmonary Exacerbation, is actively recruiting participants, sponsored by Delve Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 85 participants
- Enrollment target
- 4
- Study locations
Study Summary
The study will examine how the performance of Oscillating Lung Expansion (OLE) therapy affects the respiratory health of patients with Bronchiectasis (BE). The patient will use the BiWaze Clear system for their airway clearance therapy, instead of their previously prescribed therapy. BiWaze Clear is an FDA-cleared respiratory therapy for assisting patients in loosening and mobilizing secretions as well as treating and preventing atelectasis by providing lung expansion and high-frequency oscillation therapies, combined with aerosol delivery. The patient will perform airway clearance with BiWaze Clear as prescribed. The system uses a disposable breathing circuit, which is a single patient use, disposable circuit. The treatment duration is 6 months . The BiWaze Clear System is indicated for the mobilization of secretions, lung expansion therapy, the treatment and prevention of pulmonary atelectasis and has the ability to provide supplemental oxygen when used with an oxygen supply.
Primary Outcome
Quantify the frequency of pulmonary exacerbations over a 6-month period during BiWaze Clear therapy and compare this data to the number of exacerbations recorded in the 12 months prior to the initiation of therapy.
Conditions Studied
Interventions
- DEVICE BiWaze Clear System
Study Locations (4)
Florida
- Central Florida Pulmonary Group, P.A. - Orlando
- Treasure Coast Medical Research Group, LLC - Port Saint Lucie
- Metropolitan Clinical Research - Tamarac
- University of South Florida -Tampa General Hospital - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2025-05-20 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
What NCT06926881 shows while recruiting
NCT06926881 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 381-participant average among 13 other Bronchiectasis trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Bronchiectasis appearing as the primary indexed condition, and to 1 intervention - of which BiWaze Clear System is the first listed.
NCT06926881 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06926881 about?
NCT06926881 is a clinical study titled "OLE Therapy With BE Patients in Home Care Study". The study will examine how the performance of Oscillating Lung Expansion (OLE) therapy affects the respiratory health of patients with Bronchiectasis (BE). The patient will use the BiWaze Clear system for their airway clearance therapy, instead of their previously prescribed therapy. BiWaze Clear i...
What is the current status of trial NCT06926881?
This trial is currently recruiting. It is a NA study. The enrollment target is 85 participants. The study started on 2025-05-20. Estimated completion is 2026-08-31.
What conditions does trial NCT06926881 study?
This clinical trial studies the following conditions: Bronchiectasis, Pulmonary Exacerbation.
What interventions are being tested in trial NCT06926881?
The interventions under investigation include: BiWaze Clear System (DEVICE).
Who is sponsoring clinical trial NCT06926881?
This trial is sponsored by Delve Health, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06926881 being conducted?
This trial has 4 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bronchiectasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06926881's enrollment target sits among peer trials
85 6th of 13 higher than 8 of 13 other Bronchiectasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bronchiectasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
RECRUITING · NA
-
Acoustic Waveform Respiratory Evaluation
RECRUITING · NA
-
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
COMPLETED · NA
-
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
RECRUITING · Phase 3
-
Evaluation Of The Lung Microbiome In NTM Bronchiectasis
RECRUITING
-
Itraconazole Therapy In Bronchiectasis With Airway Mold
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI